We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Bicycle Therapeutics

News List

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors Business Wire
September 24, 2020
Bicycle Therapeutics plc today announced the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT8009.
Bicycle Therapeutics announces first patient dosed in phase I dose escalation of BT5528 in combinati pharmaceutical-business-review
May 08, 2020
Bicycle Therapeutics, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology.
Bicycle Therapeutics and Genentech sign $1.7bn cancer therapies deal pharmaceutical-technology
March 04, 2020
Bicycle Therapeutics has signed an agreement with Roche subsidiary Genentech for the discovery, development and commercialisation of immuno-oncology therapies.
Bioverativ and Bicycle Therapeutics team up in haemophilia pharmatimes
September 07, 2017
Bioverativ and Bicycle Therapeutics have announced a research collaboration focused on the discovery, development and commercialisation of innovative therapies for haemophilia and sickle cell disease.